Comment on “Membranous glomerulonephritis associated with mieloperoxidase antineutrophil cytoplasmic antibody-associated glomerulonephritis”

Nefrologia 2013;33(1):135-6

To the Editor:

We read with interest the report of Dr. Guang-Yu Zhou, about a case of Membranous Glomerulonephritis with crescentic transformation. Acute crescentic transformation is a rare but well described event in patients with membranous glomerulonephritis. The concomitant occurrence of a vasculitic glomerulonephritis and membranous nephropathy in the same patient is unusual. We report herein our similar experience. A caucasian 66-year-old man presented for rapid declining of renal function. For nearly 10 years he was suffering from hypertension and for 4 years he is having paresthesias, muscle aches in the legs and significant reduction in muscle strength with an ataxic walking. This condition was interpreted as a mixed sensori-motor polyneuropathy. He performed therapy with prednisone and azathioprine, suspended for 1 year; six months before, laboratory tests showed a serum creatinine concentration 220µmol/L and a 24-h protein excretion 0,75g/d. On admission, the physical examination showed edema and severe hypertension; we detected a 24-h protein excretion 1.1g/d, Hb: 9.1g/dl, serum creatinine concentration 550.8µmol/L, the urinalysis 2 + urine protein and 1 + urine blood. ANCA determined in serum screening test by indirect immunofluorescence and other immunological tests, including anti-nuclear antibodies (ANAs), anti-Sm antibody, anti-dsDNA antibody, anti-cyclic citrullinated peptide (CCP) antibody, and anti-glomerular basement membrane (GBM) antibody were negative; serum complement and immunoglobulin levels were normal. Liver function tests and other routine parameters were within the normal range.

Nuria Montero1, Sergio Mojal2, Julio Pascual1, Maria Jose Soler1

1 Servicio de Nefrología. Hospital del Mar. Barcelona. (Spain).
2 Institut del Mar d’Investigacions Mèdiques. Barcelona. (Spain).
Correspondence: María José Soler
Msoler@parcdesalutmar.cat
Msoler1@imim.es

Table 1. 95% limits of agreement in the Bland-Altman plot

<table>
<thead>
<tr>
<th>24-h urine total protein excretion</th>
<th>All</th>
<th>&lt;300</th>
<th>300-3499</th>
<th>&gt;3500</th>
</tr>
</thead>
<tbody>
<tr>
<td>n</td>
<td>159</td>
<td>60</td>
<td>77</td>
<td>22</td>
</tr>
<tr>
<td>Mean difference</td>
<td>252.7</td>
<td>-10.9</td>
<td>-85.8</td>
<td>2156</td>
</tr>
<tr>
<td>Standard deviation (SD)</td>
<td>1508</td>
<td>117</td>
<td>808</td>
<td>3208</td>
</tr>
<tr>
<td>95% limits of agreement (mean difference ± 2 SD)</td>
<td>(-2763, 3269)</td>
<td>(-245, 223)</td>
<td>(-1702, 1530)</td>
<td>(-4260, 8572)</td>
</tr>
</tbody>
</table>

nephropathy, except in those cases associated with systemic lupus. The immunopathogenesis of this unusual transformation is unclear. It is well recognized that patients with a crescentic glomerulonephritis have severe and often rapidly deteriorating failure. Unlike membranous nephropathy, which often has an insidious course progressing to renal failure over a period of years, patients with superimposed crescentic glomerulonephritis appear to have a more aggressive clinical course. The importance of recognizing this group of patients with membranous nephropathy and crescentic glomerulonephritis is that immunosuppressive therapy may ameliorate the progression of renal damage and in some cases early treatment was associated with useful recovery of renal function. In our case, the discontinuation of prednisone and azathioprine therapy may have facilitated the rapid progression of kidney disease.

Conflict of interest
The authors declare that there is no conflict of interest associated with this manuscript.


Gioacchino Li Cavoli1, Angelo Ferrantelli1, Luisa Bono1, Calogera Tortorici1, Carlo Giammarresi1, Rita Passantino2, Ugo Rotolo1

1 Division of Nephrology, Civic and Di Cristina Hospital. Palermo (Italy)
2 Anatomical Pathology Department, Civic and Di Cristina Hospital. Palermo (Italy)

Correspondence: Gioacchino Li Cavoli
Division of Nephrology. Civic and Di Cristina Hospital. Via Francesco Cilea 43.
90144 Palermo, Italy. gioacchinolicavoli@libero.it

Response:
Response to “Comment on 'Membranous glomerulonephritis associated with mieloperoxidase antineutrophil cytoplasmic antibody associated glomerulonephritis'”
Nefrologia 2013;33(1):136-7

They reported a case of membranous glomerulonephritis (MGN) with crescentic transformation in a ANCA-negative vasculitis which revealed no evidence of systemic lupus erythematosus (SLE), anti-glomerular basement membrane (GBM) glomerulonephritis, infection, malignancy and showed no improvement after immunosuppressive treatments. The case they presented was similar to the patient that Kwan JT et al. described previously. Although several authors have demonstrated the concomitance of MGN and ANCA-associated glomerulonephritis, MGN accompanied by ANCA-negative crescentic glomerulonephritis has been rarely encountered.

The light microscopic visualization of renal tissue in their case showed the formation of 11 crescents (3 cellular crescents, 1 fibrocellular crescent and 7 fibrotic crescents) and 11 out of 17 glomeruli were globally sclerotic. These histopathological changes indicate the patient has reached to an advanced stage of crescentic glomerulonephritis and the renal disease has progressed to the sclerotic phase at the time of renal biopsy. Nasr SH et al. reported that the percentage of globally sclerotic glomeruli correlated with nonresponse to immunosuppressive agents. This is why the patient showed no improvement after treated with steroid plus cyclophosphamide and started chronic haemodialysis treatment eventually. By contrast, our case showed 2 sclerosed glomeruli out of 19 glomeruli, the formation of 9 crescents including 4 cellular crescents and 5 fibrocellular crescents, as well as the fibrinoid necrosis lesions upon light microscopy. This indicates our patient might be at the relatively early stage of crescentic glomerulonephritis and the renal biopsy findings may interpret the better response to immunosuppressive treatments in our case.

Concerning the prognosis of this group of patients, Nasr SH et al. reported that 50% of patients had reached endpoints of end-stage renal stage (ESRD) or death whether or not treated with immunosuppressive agents and the only independent predictor of progression to